- RxActuator launched its first Clinical Advisory Board with seven specialists spanning pain management, pharmacology, internal medicine, rehabilitation, oncology, hospice care and equine surgery.
- The board will help guide clinical protocols, research initiatives, continuing education programs and post-market validation efforts.
- Members include clinicians from private practice, specialty referral centers and leading veterinary academic institutions.
- The company’s Mini-Infuser® platform is designed to deliver continuous-rate infusion (CRI) therapy in outpatient settings.
- RxActuator says the technology can help reduce hospitalization costs while freeing ICU capacity at veterinary hospitals.
RxActuator™ has established its inaugural Clinical Advisory Board (CAB), bringing together seven veterinary specialists to support the development and adoption of outpatient continuous-rate infusion (CRI) therapy for companion animals.
The Raleigh, North Carolina-based veterinary medical device company said the board will provide guidance on clinical protocols, evidence generation, continuing education initiatives and peer-reviewed research related to its wearable Mini-Infuser® platform.
According to the company, the advisory group reflects growing interest in ‘hospital-at-home’ care models that allow certain patients to receive infusion therapy outside of traditional inpatient settings.
Advisory Board Members Announced
The founding members of the Clinical Advisory Board include:
- Dr. James (Jamie) Gaynor, Black Dog Veterinary Anesthesia Services and Buffalo Mountain Animal Hospital
- Dr. Mark Papich, North Carolina State University College of Veterinary Medicine
- Dr. Tyler Carmack, Caring Pathways and Hampton Roads Veterinary Hospice
- Dr. Harry Cridge, board-certified small animal internal medicine specialist
- Dr. Lindsey Fry, Fryday Veterinary Mobility and Pain Management
- Dr. Greg Staller, Running ‘S’ Equine Veterinary Services
- Dr. Luke Wittenburg, UC Davis School of Veterinary Medicine
Dr. Gaynor will serve as chair of the advisory board.
Focus on Expanding Outpatient Treatment Options
RxActuator said the board’s responsibilities will include helping develop treatment protocols, supporting clinical validation efforts and representing the technology at veterinary specialty meetings, including ACVS, IVECCS, ACVAA, IVAPM, ACVIM, the Veterinary Cancer Society, IAAHPC and AAEP.
The company believes outpatient infusion therapy could help address several ongoing challenges facing veterinary practices, including staffing shortages, ICU capacity constraints and rising treatment costs.
Recent industry surveys have highlighted the impact of financial considerations on treatment decisions, with many veterinarians reporting that cost remains a significant barrier to care acceptance.
Wearable Infusion Platform Designed for Home Use
The Mini-Infuser® is a wearable, disposable infusion device designed to deliver continuous drug therapy without batteries, software or programming requirements. The platform uses a patented water-activated polymer actuator to administer medications over an extended period.
RxActuator cites multiple peer-reviewed publications supporting the technology, including a 2025 study evaluating outpatient management of pancreatitis patients. The company reports that the device has been used in more than 90 veterinary clinics across 26 U.S. states and three countries.
As veterinary medicine continues to explore alternatives to traditional inpatient care, RxActuator says the advisory board will play a central role in shaping best practices and expanding the clinical evidence supporting outpatient infusion therapy.
Information sourced from an RxActuator press release.
